Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying the stock. We monitor 13F filings and institutional buying patterns because large investors often have superior information.
This analysis evaluates Biogen Inc.’s (NASDAQ: BIIB) recently announced definitive licensing agreement with TJ Biopharma for Greater China rights to experimental antibody felzartamab, a key late-stage asset in the firm’s immunology pipeline. The $850 million total potential deal unlocks full global
Biogen Inc. (BIIB) - Secures Exclusive Global Felzartamab Rights via Greater China Licensing Deal, Shares Rally - Beat Estimates
BIIB - Stock Analysis
3404 Comments
1348 Likes
1
Jionna
Influential Reader
2 hours ago
Pullback levels coincide with recent support zones, reinforcing stability.
👍 85
Reply
2
Kashun
Senior Contributor
5 hours ago
This feels like a warning without words.
👍 264
Reply
3
Maxey
Experienced Member
1 day ago
I read this and now I feel early and late at the same time.
👍 263
Reply
4
Paigelynn
Legendary User
1 day ago
Anyone else watching without saying anything?
👍 156
Reply
5
Juell
Community Member
2 days ago
Access expert-driven US stock research and daily updates focused on identifying growth opportunities while maintaining a strong emphasis on risk control. We understand that protecting your capital is just as important as generating returns, and our strategies reflect this balanced approach.
👍 241
Reply
© 2026 Market Analysis. All data is for informational purposes only.